on Zomedica Corp. (NASDAQ:ZOM)
Zomedica Launches Equine Cortisol Assay for TRUFORMA Platform
Zomedica Corp. (NYSE American:ZOM), a veterinary health company, announced the commercial release of its equine cortisol assay for the TRUFORMA diagnostic platform. This enables stall-side testing, offering rapid decisions for equine veterinarians.
Dr. T.J. Barclay highlighted the importance of cortisol measurement in sick foals, noting that results traditionally took days from reference labs. The new assay now provides results in minutes, helping veterinarians make timely, life-saving treatments.
Kelsey Hart, DVM, PhD, stated that real-time cortisol measurements will be transformative in diagnosing and treating critical illness-related cortisol insufficiency (CIRCI) in foals and sick horses.
Zomedica's CEO, Larry Heaton, emphasized the positive feedback from their first equine assay and the significant potential market this new assay will access. With the TRUFORMA platform, Zomedica is positioned to expand into the European market, targeting a $1.5 billion annual recurring revenue in the US and a $3.6 billion forecasted market by 2028.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Zomedica Corp. news